The next social challenge to public health: the information environment.pptx
Coronary Stent Deisgn Part C
1. Coronary Stents Design
Part C – Biodegradable stents and
Future Solutions
Dr. Amir Kraitzer
The contents of materials available on this presentation are reserved. Content may not be reproduced,
published, or transferred except with the prior written permission of Dr. Amir Kraitzer
3. Rational for Biodegradable stents
Metal stent drawbacks Biodegradable stent advantages
Cause permanent physical May eliminate early and late
irritation complications of bare-metal
Risk of long term endothelial stents
Restore the vasoreactivity
dysfunction and chronic
Allow a gradual transfer of the
inflammation
Metal have thrombogenic
mechanical load to the vessel
Higher capacity for drug
properties incorporation and complex
Inability for the vessel to release kinetics
restore its a normal Facilitate re-intervention
physiology
The need for a permanent prosthesis decreases
dramatically 6 months post-implantation
4. Design considerations
Overall time and rate of degradation
a very rapid degradation rate can be associated with
inflammation
Biocompatibility of degradation products to prevent
toxicity
Mechanical properties
Mechanical recoil
Strut size
Creep
Embolization of degraded particles
Drug load
Radiopacity
5. Igaki-Tamai BDS
A bioresorbable zigzag coil design
PLLA (Initial MW=183KDa)
Initial clinical trial results proved
efficacy and safety (2000)
On November 2007 the stent
obtained CE mark indicated for
peripheral artery
Igaki Tamai Stents loaded with
ST638 (Tranilast) reduced
neointima formation in animals
6. BVS (Abbott) Drug Eluting BDS
Drug: Everolimus
Base Polymer: PLLA
Coating: PDLLA
Releases 80% of its drug in 28 days
Maintains radial strength for 3
months
Mass loss after 6 months, complete
resorption in two years
Good clinical outcomes with two
years follow-up
No occurrence of thrombosis
between 6 and 24 months
Source: Abbott Vascular, AP2929018Rev A
8. REVA Drug Eluting BDS
Drug: Paclitaxel
Base polymer: Tyrosine-
derived polycarbonate platform
Low recoil (<1%)
Slide and lock design
Tunable resorption rate
Radiopacity is achieved by the
incorporation of iodine
molecules
9. Absorbable Magnesium Stent
(Medtronic)
Radial strength and recoil is
similar to BMS
4-month clinical results: late
loss is comparable to BMS
Further improvement in stent
design due to:
Early recoil
Fast degradation
Neointima formation
14. Genous Stent
Precilinical trials
1 hour post- deployment:
90% cell coverage
1st Clinical trial
demonstrated safety
and feasibility
2nd Clinical trial
demonstrated late loss
is comparable to BMS
Endothelial Progenitor Cell Capture by Stents Coated With
Antibody Against CD34 : The HEALING-FIM Registry, Aoki et
al, J. Am. Coll. Cardiol. 2005;45;1574-1579
15. Drug eluting balloon
SeQuent® Please
Provides uniform drug dose
Reduces thrombosis risk and
enables shorter dual anti-
platelet regimen
Allows significantly lower drug
dose compared with DES
Two forms of release
Drug and spacer
Nanoparticles
16. Core/shell fiber structure concept
I. Good mechanical properties
II. Effective drug release profile
III. Porous structured coating
allows controlled release
18. References
Amir Kraitzer, Yoel Kloog, Meital Zilberman, Approaches for
Prevention of Restenosis, J Biomed Mater Res Part B: Appl
Biomater 85B: 583–603, 2008
Gladius Lewis, Review: Materials, Fluid Dynamics, and Solid
Mechanics Aspects of Coronary Artery Stents: A State-of-the-Art
Review, Biomed Mater Res Part B: Appl Biomater 86B: 569–590,
2008
Meital Zilberman, Amir Kraitzer, Orly Grinberg and Jonathan J.
Elsner, Drug-Eluting Medical Implants, In : Handbook of European
Pharmacology, 2008
Update on Bioabsorbable Stents: From Bench to Clinical, RON
WAKSMAN, Journal of Interventional Cardiology, Vol. 19, No. 5,
2006